Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's ...

Other Phenotypes Premature death, attributed to hindbrain tauopathy, generally occurs between eight and 12 months (Dutschmann et al., 2010). Premature death is preceded by weight loss, hyperkyphosis, ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

Zeroing in on that pathway, the researchers found that in the absence of the lysosomal protein prosaposin, glycosphingolipids accumulate in the lysosomes, setting off oxidative stress. This results in ...

However, diagnostic tests do not need FDA approval to be marketed to the public. They can clear a lower bar by becoming CLIA-approved, meaning the assay has good test-retest reproducibility. Quest's ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

Two immunoprecipitation-mass-spectrometry assays came out on top, accurately pegging people who had plaques 83 to 87 percent of the time. The other assays hovered between 64 to 80 percent.

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...